Association of Copeptin and N-Terminal proBNP Concentrations With Risk of Cardiovascular Death in Older Patients With Symptoms of Heart Failure

被引:123
作者
Alehagen, Urban [1 ]
Dahlstroem, Ulf [1 ]
Rehfeld, Jens F. [2 ]
Goetze, Jens P. [2 ]
机构
[1] Linkoping Univ, Div Cardiovasc Med, Dept Med & Hlth Sci,Cty Council Ostergotland, Fac Hlth Sci,Dept Cardiol UHL, SE-58185 Linkoping, Sweden
[2] Univ Copenhagen, Rigshosp, Dept Clin Biochem, DK-2100 Copenhagen, Denmark
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2011年 / 305卷 / 20期
关键词
ACUTE MYOCARDIAL-INFARCTION; ARGININE-VASOPRESSIN INCREASES; LEFT-VENTRICULAR DYSFUNCTION; NATRIURETIC PEPTIDE; PROVASOPRESSIN COPEPTIN; PROGNOSTIC MARKER; DIAGNOSIS; PLASMA; BNP;
D O I
10.1001/jama.2011.666
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Measurement of plasma concentrations of the biomarker copeptin may help identify patients with heart failure at high and low risk of mortality, although the value of copeptin measurement in elderly patients is not fully known. Objective To evaluate the association between plasma concentrations of copeptin, a surrogate marker of vasopressin, combined with concentrations of the N-terminal fragment of the precursor to B-type natriuretic peptide (NT-proBNP), and mortality in a cohort of elderly patients with symptoms of heart failure. Design, Setting, and Participants Primary health care population in Sweden enrolling 470 elderly patients with heart failure symptoms between January and December 1996. Clinical examination, echocardiography, and measurement of peptide concentrations were performed, with follow-up through December 2009. Main Outcome Measures All-cause mortality and cardiovascular mortality. Results After a median follow-up of 13 years, there were 226 deaths from all causes, including 146 deaths from cardiovascular causes. Increased concentration of copeptin was associated with increased risk of all-cause mortality (fourth quartile vs first quartile: 69.5% vs 38.5%, respectively; hazard ratio [HR], 2.04 [95% confidence interval {CI}, 1.38-3.02]) and cardiovascular mortality (fourth quartile vs first quartile: 46.6% vs 26.5%; HR, 1.94 [95% CI, 1.20-3.13]). The combination of elevated NT-proBNP concentrations and elevated copeptin concentrations also was associated with increased risk of all-cause mortality (copeptin fourth quartile: HR, 1.63 [95% CI, 1.08-2.47]; P=.01; NT-proBNP fourth quartile: HR, 3.17 [95% CI, 2.02-4.98]; P<.001). Using the 2 biomarkers simultaneously in the evaluation of cardiovascular mortality, there was a significant association for copeptin in the presence of NT-proBNP (log likelihood trend test, P=.048) and a significant association for NT-proBNP (fourth quartile: HR, 4.68 [95% CI 2.63-8.34]; P<.001). Conclusion Among elderly patients with symptoms of heart failure, elevated concentrations of copeptin and the combination of elevated concentrations of copeptin and NT-proBNP were associated with increased risk of all-cause mortality. JAMA. 2011; 305(20): 2088-2095
引用
收藏
页码:2088 / 2095
页数:8
相关论文
共 27 条
[1]  
Alehagen U., 2002, HeartDrug, V2, P211, DOI 10.1159/000067723
[2]   Utility of the amino-terminal fragment of pro-brain natriuretic peptide in plasma for the evaluation of cardiac dysfunction in elderly patients in primary health care [J].
Alehagen, U ;
Lindstedt, G ;
Eriksson, H ;
Dahlström, U .
CLINICAL CHEMISTRY, 2003, 49 (08) :1337-1346
[3]   BNP test utilization for CHF in community hospital practice [J].
Apple, FS ;
Trinity, E ;
Steen, J ;
Prawer, S ;
Wu, AHB .
CLINICA CHIMICA ACTA, 2003, 328 (1-2) :191-193
[4]   Neurohormonal activation in congestive heart failure and the role of vasopressin [J].
Chatterjee, K .
AMERICAN JOURNAL OF CARDIOLOGY, 2005, 95 (9A) :8B-13B
[5]  
CHOY AMJ, 1994, BRIT HEART J, V72, P16
[6]   COMPARING THE AREAS UNDER 2 OR MORE CORRELATED RECEIVER OPERATING CHARACTERISTIC CURVES - A NONPARAMETRIC APPROACH [J].
DELONG, ER ;
DELONG, DM ;
CLARKEPEARSON, DI .
BIOMETRICS, 1988, 44 (03) :837-845
[7]   Evaluation of novel biomarkers for the diagnosis of acute destabilised heart failure in patients with shortness of breath [J].
Dieplinger, B. ;
Gegenhuber, A. ;
Haltmayer, M. ;
Mueller, T. .
HEART, 2009, 95 (18) :1508-1513
[8]   VASOPRESSIN REDUCES CARDIAC-FUNCTION AND AUGMENTS CARDIOPULMONARY BAROREFLEX RESISTANCE INCREASES IN MAN [J].
EBERT, TJ ;
COWLEY, AW ;
SKELTON, M .
JOURNAL OF CLINICAL INVESTIGATION, 1986, 77 (04) :1136-1142
[9]   Arginine vasopressin increases iNOS-NO system activity in cardiac fibroblasts through NF-κB activation and its relation with myocardial fibrosis [J].
Fan, Yan-Hong ;
Zhao, Lian-You ;
Zheng, Qiang-Sun ;
Dong, Hui ;
Wang, Hai-Chang ;
Yang, Xue-dong .
LIFE SCIENCES, 2007, 81 (04) :327-335
[10]   Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor [J].
Fukuzawa, J ;
Haneda, T ;
Kikuchi, K .
MOLECULAR AND CELLULAR BIOCHEMISTRY, 1999, 195 (1-2) :93-98